Which has grown faster, NTLA or SGRY?

Over the past five years, SGRY grew revenue faster — NTLA at a 7.31% CAGR versus SGRY at 9.90%.

How have NTLA and SGRY total returns compared?

Over the past 10 years, NTLA delivered -3.03% and SGRY delivered -3.96% annualized total return. Past performance doesn't predict future results.

Intellia Therapeutics, Inc. (NTLA) vs Surgery Partners, Inc. (SGRY)

A side-by-side comparison of Intellia Therapeutics, Inc. and Surgery Partners, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

NTLA

Intellia Therapeutics, Inc.

$1.75B

$12.50HealthcareDelayed quote: Oct 6, 2026, 2:50 PM EDT

SGRY

Surgery Partners, Inc.

$1.76B

$13.49HealthcareDelayed quote: Oct 6, 2026, 2:50 PM EDT

Total return — NTLA vs SGRY

growth of $100 · dividends reinvested · last 10y

NTLA -26.5% (-3.0%/yr)SGRY -33.5% (-4.0%/yr)NTLA compounded faster over this window

NTLA SGRY

NTLA vs SGRY: by the numbers

•SGRY is the larger company ($1.76B vs $1.75B market cap).
•Both run net losses; SGRY's is the smaller (-2.63% vs -672.16% net margin).
•SGRY grew revenue faster over the past five years (9.90% vs 7.31% CAGR).

Metrics side by side

Valuation

Metric	NTLA	SGRY
Forward P/E	N/A	33.14
P/S ratio	29.35	0.52
P/B ratio	2.40	1.06
EV / EBITDA	N/A	9.63
FCF yield	N/A	10.63%

Profitability

Metric	NTLA	SGRY
Gross margin	76.47%	21.37%
Operating margin	-651.67%	11.89%
Net margin	-672.16%	-2.63%
ROE	-54.96%	-5.30%
ROIC	-54.45%	4.23%

Growth (annualized)

Metric	NTLA	SGRY
Revenue CAGR (5Y)	7.31%	9.90%
FCF CAGR (5Y)	N/A	-0.84%
Total return CAGR (5Y)	-37.13%	-20.85%

Frequently asked

Which has grown faster, NTLA or SGRY?: Over the past five years, SGRY grew revenue faster — NTLA at a 7.31% CAGR versus SGRY at 9.90%.
How have NTLA and SGRY total returns compared?: Over the past 10 years, NTLA delivered -3.03% and SGRY delivered -3.96% annualized total return. Past performance doesn't predict future results.

Go deeper

Full NTLA analysis Full SGRY analysis Interactive comparison tool

Dig into the metrics

Intellia Therapeutics ROE Surgery Partners ROE Intellia Therapeutics operating margin Surgery Partners operating margin Intellia Therapeutics revenue growth Surgery Partners revenue growth Intellia Therapeutics free cash flow Surgery Partners free cash flow

Intellia Therapeutics & Surgery Partners appear in these rankings

Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.